Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Palo Alto, California 94304, United States
State College, Pennsylvania 16803, United States
Rosario, Santa Fe, S2002, Argentina
Lillie Cedex, 59037, France
Hyderabad, Andhra Pradesh 500084, India
Zapapan, Jalisco 45030, Mexico
Ul. Piotrkowska 177, 90-447, Poland
Kozlu, 67000, Taiwan
Izmit/Kocaeli, 41380, Turkey (Türkiye)
Corbridge Road, NE46 1QJ, United Kingdom
Lancashire Blackpool, FY3 8NR, United Kingdom
North Manchester Science Park, M15 6SX, United Kingdom